JARUSHKA NAIDOO, MBBCH, MD

Adjunct Assistant Professor of Oncology
Johns Hopkins University
Baltimore, Maryland
Consultant Medical Oncologist
Beaumont Hospital Dublin
Dublin, Ireland

JARUSHKA NAIDOO, MBBCH, MD

Adjunct Assistant Professor of Oncology
Johns Hopkins University
Baltimore, Maryland

Consultant Medical Oncologist
Beaumont Hospital Dublin
Dublin, Ireland

BIOGRAPHY

Jarushka Naidoo, MBBCH, MD, is a medical oncologist and an Adjunct Assistant Professor of Oncology in the Upper Aerodigestive Division at the Bloomberg-Kimmel Institute for Cancer Immunotherapy of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, Maryland, and a consultant medical oncologist at Beaumont Hospital Dublin in Dublin, Ireland.

She serves in multiple leadership roles including Chair of Clinical Trials Ireland of the Irish Lung Cancer Alliance, Co-Chair of the Irish National Immune-Related Toxicity Team, Chair of the Immunotherapy Subcommittee of NRG Oncology, Co-Chair of the Lung Cancer Committee of the Association for Community Cancer Centers, and Co-Chair of the Lung Cancer Committee of the Institute for Clinical Immuno-Oncology. Dr Naidoo is a member of the Immune-Toxicity Guideline Panel of the National Comprehensive Cancer Network, Lung Cancer and Cancer Control and Symptom Science Committees of the Eastern Cooperative Oncology Group, Immunotherapy Toxicity Guideline Committee of the American Society of Clinical Oncology (ASCO), and Immuno-Oncology Institute Working Group of the Association for Community Cancer Centers. She is the recipient of multiple awards including a Young Investigator Award given by Lung Cancer Foundation of America/International Association for the Study of Lung Cancer/Bristol-Myers Squibb (2019) and a Merit Award given by ASCO/Conquer Cancer Foundation (2015). Dr Naidoo is a member of the 2021-2022 ASCO Leadership Development Program. She serves on the Editorial Board of Frontiers in Oncology and Cancer Investigation and is a reviewer for at least 24 peer-reviewed journals.

She has authored or coauthored at least 68 peer-reviewed journal articles and at least 1 book chapter. Dr Naidoo is a member of ASCO, the European Society of Medical Oncology, the International Association for the Study of Lung Cancer, the Society for Immunotherapy in Cancer, and the American Association for Cancer Research. Her clinical research focus includes lung cancer, thoracic malignancies, and immunotherapy. Dr Naidoo has special research interest in clinical trials of combinations of immunotherapies for the treatment of lung cancer and other thoracic cancers as well as the side effects of immunotherapy for cancer.